Stoke Therapeutics, Inc.
STOK · XNASCIK 1623526fmd_11YC9PHE6TEYD6F6X4NXECABHNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 12 | 9 | 37 | 184 |
| Research and development | 8 | 24 | 32 | 54 | 78 | 82 | 89 | 138 |
| Selling, general and administrative | – | – | – | – | – | – | 49 | 67 |
| Total operating expenses | 13 | 36 | 53 | 86 | 117 | 124 | 138 | 205 |
| Operating income | (13) | (36) | (53) | (86) | (104) | (115) | (101) | (21) |
| Interest expense | – | – | – | – | – | 0 | 0 | 0 |
| Interest and investment income | 0 | 3 | 1 | – | – | 10 | 13 | 14 |
| Other non-operating income (expense) | 0 | 3 | 1 | 0 | 3 | 10 | 12 | 14 |
| Income tax expense | – | – | – | – | – | – | – | 0 |
| Net income | (13) | (32) | (52) | (86) | (101) | (105) | (89) | (7) |